{
  "docId": "019de514-4d4c-7369-a2bf-f736423e3911",
  "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53",
  "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides",
  "authorId": "imara",
  "authorName": "Enliven Therapeutics / Imara",
  "documentKindSlug": "press-release",
  "documentKindLabel": "Press release",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 45,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "before_after",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Uses a before-after-bridge structure to contrast market limitations with product advantages.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/13",
  "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911",
  "deckJsonHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911.json",
  "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.05,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "CNS = Central nervous. IM = Insertion mutation. NSCLC = Non-small cell lung caner. TKI = Tyrosine kinase inhibitor. NHP = non-human primate.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1d9fde8-2527-4513-8eb2-fe30474b74bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.43,
        "x": 0.06,
        "y": 0.2
      },
      "kind": "list",
      "text": "Current HER2 TKI Landscape: High homology makes selectivity difficult; dual EGFR/HER2 inhibitors are dose-limited; Tucatinib lacks potency against key mutants; insufficient CNS penetration.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33b13e77-2a35-450d-9569-b4f7c6e45729",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "list",
      "text": "Our HER2 Candidate: ELVN-002: Irreversibly inhibits HER2 and key mutations; spares EGFR to prevent toxicity; superior pre-clinical activity and improved safety margin.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54ebe6f6-7a81-414c-87f1-043151bf9efa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "We believe that our product candidate, if it achieves the target profile, will be able to achieve an improved therapeutic index compared to current approved and investigational TKIs as well as provide a meaningful therapeutic option to patients with brain metastases",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e427116d-7bff-496f-b08b-30fd1388d9bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ELVN-002: Opportunity for a Selective Irreversible Pan-Mutant HER2 TKI",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca536866-8a77-4575-9c40-8b7c4c47ace0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "31d197d2-ce55-49bd-b28c-5499e303f8cc",
      "evidence": "Contrasts current landscape limitations with the proposed solution and future benefit.",
      "confidence": 0.95
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 9,
      "beatId": "f1c5daaa-0597-4f81-b694-1845468beefb",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document identifies a significant need for better treatment options for chronic myeloid leukemia and other cancers.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 29,
      "from": 10,
      "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 16,
      "from": 12,
      "beatId": "c5896f5c-788f-4fd0-9b6e-5b25251433b2",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The document presents the key features and benefits of ELVN-001 and ELVN-002, including their clinical focus and target product profiles.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}